350 Shares in Cencora, Inc. (NYSE:COR) Bought by Evermay Wealth Management LLC

Evermay Wealth Management LLC purchased a new stake in Cencora, Inc. (NYSE:COR) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 350 shares of the company’s stock, valued at approximately $85,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in COR. Fisher Asset Management LLC purchased a new stake in Cencora in the fourth quarter valued at about $244,000. Trust Co. of Vermont purchased a new stake in Cencora in the fourth quarter valued at about $62,000. Wahed Invest LLC acquired a new position in shares of Cencora in the fourth quarter valued at about $567,000. Vanguard Group Inc. acquired a new position in shares of Cencora in the fourth quarter valued at about $4,212,508,000. Finally, Hennessy Advisors Inc. acquired a new position in shares of Cencora in the fourth quarter valued at about $3,307,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. SVB Leerink reissued an “outperform” rating and issued a $275.00 price objective on shares of Cencora in a report on Thursday, June 27th. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Citigroup increased their price objective on Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Finally, Robert W. Baird increased their price objective on Cencora from $280.00 to $285.00 and gave the company an “outperform” rating in a report on Tuesday, July 9th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $238.78.

Insiders Place Their Bets

In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the firm’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the completion of the sale, the chief executive officer now owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of Cencora stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the completion of the sale, the insider now directly owns 24,418,171 shares of the company’s stock, valued at approximately $5,252,836,945.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the sale, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The disclosure for this sale can be found here. Insiders sold a total of 1,899,112 shares of company stock valued at $408,654,376 over the last quarter. 15.80% of the stock is owned by insiders.

Cencora Stock Performance

Cencora stock traded up $1.13 during midday trading on Thursday, hitting $227.11. 969,411 shares of the company were exchanged, compared to its average volume of 1,363,092. The firm has a market capitalization of $45.30 billion, a PE ratio of 24.85, a price-to-earnings-growth ratio of 1.56 and a beta of 0.45. Cencora, Inc. has a fifty-two week low of $171.65 and a fifty-two week high of $246.75. The business has a fifty day simple moving average of $226.85 and a two-hundred day simple moving average of $230.36. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.65 by $0.15. The company had revenue of $68.41 billion for the quarter, compared to the consensus estimate of $70.60 billion. Cencora had a return on equity of 268.67% and a net margin of 0.67%. Cencora’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.50 earnings per share. On average, sell-side analysts forecast that Cencora, Inc. will post 13.46 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Investors of record on Friday, May 10th were given a dividend of $0.51 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $2.04 dividend on an annualized basis and a yield of 0.90%. Cencora’s payout ratio is 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.